GSK Consumer Healthcare commends FDA nicotine replacement therapy proposals
PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare today commended the proposals by the U.S. Food and Drug Administration after the administration announced recommendations to remove certain warning statements and modifications of the instructions for use of nicotine replacement therapy products.
According to the statement released by GSK Consumer Healthcare:
"As leaders in smoking cessation, GlaxoSmithKline Consumer Healthcare commends the FDA on this action and believes this is a positive step to help more smokers quit and will work with the FDA to implement these changes to our product labeling as soon as possible. The changes help eliminate barriers for smokers and include updates to the warnings and directions sections in the current label."
"The FDA’s conclusions include:
There are no significant safety concerns associated with the concomitant use of NRT products with other nicotine containing products.
There are no significant safety risks associated with the use of NRT products for longer than the labeled 12 weeks of use.
Currently marketed NRT products do not appear to have significant potential for abuse or dependence."
"FDA makes these recommendations based on extensive and reassuring safety and efficacy research on over-the-counter NRT, like Nicorette and NicoDerm CQ, which have helped millions of smokers around the world quit by gradually weaning them off of their tobacco addiction. NRT products have been studied in more than 110 clinical trials involving more than 40,000 participants demonstrating their safety and efficacy profile."
E.p.t announces partnership with the American Fertility Association
TREVOSE, Pa. — E.p.t, creator of the original home pregnancy test, has partnered with the American Fertility Association to support the vast community of those who are actively trying to conceive, or TTC, during National Infertility Awareness Month this April.
In an effort to support the TTC community, e.p.t will make a donation of $1 to the AFA for each unique interaction (i.e., like, share and/or comment) on the brand’s Facebook page during the month of April, up to a total of $5,000 during the first phase of the partnership. All contributions enable the AFA to continue to provide outstanding education, support and advocacy to those dealing with infertility, striving to build their family of choice or looking to preserve their fertility.
“We know many of our customers struggle with infertility, so the TTC community holds a special place in the hearts of all of us at e.p.t,” said Jennifer Moyer, VP marketing for INSIGHT Pharmaceuticals, the parent company of e.p.t. “The AFA’s mission to provide resources for those with fertility issues plays a pivotal role in the lives of families in need of support, and we are thrilled to partner with the organization on this effort.”
The American Fertility Association is committed to helping people create and build families by offering outreach programs and timely education information, focused on infertility prevention and treatment. The AFA provides materials and services, free of charge, to everyone without reservation.
“The American Fertility Association is proud to join e.p.t in our shared mission to support the TTC community,” said Corey Whelan, program director at The AFA. “Imagine life without infertility, a world where all hopeful parents could have a child. The AFA is working hard to make this a reality, and we are delighted that e.p.t is dedicated to supporting this goal.”
According to the Centers for Disease Control and Prevention, more than 7.3 million women suffer from infertility, which is defined as the inability to get pregnant after six to 12 months of trying to conceive. This number averages to 1-in-8 women who are battling infertility.
“Women and couples struggling with infertility often feel misunderstood, isolated or as though they are uniquely ‘broken,’” said Dr. Yvonne Bohn, OB/GYN and one of the stars of the Discovery Health series “Deliver Me.” “The truth is, infertility is more common than most think, and those suffering are far from alone. Millions of women and couples battle infertility — including many of our patients — and as doctors, we’re with them every step of the way.”
Lifestyles launches new Turbo condoms
ISELIN, N.J. — The makers of LifeStyles condoms today announced the release of the new Turbo condom. The Turbo condom is lubricated inside and out with LifeStyles’ proprietary Excite gel.
The Excite gel lubricant contains both menthol and L-Arginine. L-Arginine is a natural amino acid that has been shown to help increase circulation by relaxing and dilating blood vessels to enhance blood flow. The menthol produces a tingling sensation to intensify pleasure.
"As part of LifeStyles condoms commitment to innovation and consumer satisfaction, we are thrilled to announce the launch of Turbo," commented Carol Carrozza, VP sales and marketing North America for Ansell Healthcare, the makers of LifeStyles condoms. "With Turbo, consumers will discover an extraordinary and unique way to enjoy sex with a condom, serving the dual role of promoting safe sex while enhancing the sexual experience."
LifeStyles Turbo condom is made from premium grade latex.
Turbo condoms are available at a wide range of big box retailers, drugstores and grocery and stores across the country. The MSRP for a 10-count package of TURBO is $13.99 to $16.99.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.